Journal: Cell Death & Disease

Article Title: Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma

doi: 10.1038/s41419-019-1372-0

Figure Lengend Snippet: a Analysis of cell viability (normalized Resazurin signal to DMSO control) in A673 Ewing sarcoma (EwS) cells treated for 72 h with the indicated concentrations of MK-3207. The graph shows the dose-dependent relative Resazurin signal. Data are represented as mean and SEM ( n = 12); unpaired two-tailed Student’s t test. b Comparison of relative Resazurin signal of A673 cells carrying a dox-inducible shRNA against RAMP1 treated with 150 µM of MK-3207 with/without knockdown of RAMP1 by additional addition of 1 µg/ml dox to the growth medium. Data are represented as mean and SEM ( n = 3); unpaired two-tailed Student’s t test. c Analysis of colony-forming capacity of A673 (left panel) and RDES (right panel) EwS cells under treatment with the small molecule CGRP receptor inhibitors MK-3207 (20 µM) or BIBN-4096 (Olcegepant; 100 µM). DMSO served as control for treatment. Representative images of the colonies are shown below. Data are represented as mean and SEM ( n = 3); unpaired two-tailed Student’s t test. d Analysis of sphere-formation capacity of A673 (left panel) and RDES (right panel) EwS cells under treatment with the small molecule CGRP receptor inhibitors MK-3207 (20 µM) or BIBN-4096 (Olcegepant; 100 µM). DMSO served as control for treatment. Sphere index was calculated by addition of diameters of all existing spheres in one well divided by diameter of spheres in the control well. Data are represented as mean and SEM ( n = 3); unpaired two-tailed Student’s t test. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001

Article Snippet: Forty-eight hours after seeding, inhibitors were added at final concentrations of 100 µM for BIBN-4096 (Olcegepant; R&D systems, Minneapolis, MN, USA) and 20 µM for MK-3207 (AdooQ Bioscience).

Techniques: Two Tailed Test, shRNA

Journal: bioRxiv

Article Title: Identifying the Brain Circuits that Regulate Pain-Induced Sleep Disturbances

doi: 10.1101/2024.12.20.629596

Figure Lengend Snippet: Pharmacological blocking of CGRP or NMDA receptors in the SI-BF or CeA during AIP-induced sleep loss: The experimental protocol for recording sleep with or without AIP and after blocking of either the CGRP (BIBN4096BS; 80µg/ µl) or NMDA (AP-5; 40µg/ µl) receptors with 200nl of antagonists injected bilaterally in either the SI- BF or the CeA using the injectors cannulas and the infusion/withdrawal programmable dual syringe pump ( a ). Photomicrographs of Nissl’s-stained brain sections ( b ) show the guide-cannula tracks used to insert the injector cannulas, whose tips were marked using thionine stain, in the vicinity (within a radius of 1-1.5mm) of the substantia innominata (SI, b1 ) in the basal forebrain (BF) and the central nucleus of the amygdala (CeA, b2 ). Asterisks mark the tip of the injector cannula that extended the guide cannulas by 1 mm, observed either in the same or adjacent section that lie within 1mm of the PBel CGRP terminal sites. Scale in b1 and b2 is 0.5mm. Graphs in c show the percentage (mean ± SEM) of time spent in NREM sleep for each hour ( c1) and in 3h bins ( c2 ) after AIP. The blue rectangle represents the dark phase. The groups were statistically compared using a two-way (treatment X time) ANOVA, followed by Holms-sidak method for multiple comparisons, where **- P<0.001; *- P<0.01. The color of the asterisk compares AIP to the group representing the color in the graph.

Article Snippet: For the pharmacological blocking, we used CGRP receptor blocker injections, BIBN (BIBN4096BS; 80μg/ml; Boehringer Ingelheim Pharma KG, Biberach, Germany) and NMDA receptor blocker injection, AP-5 (40μg/ml), which were delivered using the injector cannula that was placed in the guide and extending past the tip of the guide by 1mm.

Techniques: Blocking Assay, Injection, Staining

Journal: Mediators of Inflammation

Article Title: The Effects of Six Weeks of Endurance Training and CGRP Inhibition on Nrf2 and AKT Expression in the Hippocampal Tissue of Male Wistar Rats

doi: 10.1155/2022/1610293

Figure Lengend Snippet: Comparison of gene expression changes in groups.

Article Snippet: CGRP inhibition in the relevant group was performed through intravenous injection of CGRP receptor antagonist (compound) (BIBN4096BS from Merck Company, Darmstadt, Germany) using a 1 ml insulin syringe at a dose of 0.25 mg/kg every day and few hours before the treadmill exercise [ ].

Techniques: Expressing, Inhibition

Journal: Mediators of Inflammation

Article Title: The Effects of Six Weeks of Endurance Training and CGRP Inhibition on Nrf2 and AKT Expression in the Hippocampal Tissue of Male Wistar Rats

doi: 10.1155/2022/1610293

Figure Lengend Snippet: Means and standard deviations of rats' weights in study groups.

Article Snippet: CGRP inhibition in the relevant group was performed through intravenous injection of CGRP receptor antagonist (compound) (BIBN4096BS from Merck Company, Darmstadt, Germany) using a 1 ml insulin syringe at a dose of 0.25 mg/kg every day and few hours before the treadmill exercise [ ].

Techniques: Inhibition

Journal: Drugs

Article Title: Zavegepant: First Approval

doi: 10.1007/s40265-023-01885-6

Figure Lengend Snippet:

Article Snippet: The acquisition brought to Pfizer a portfolio of promising CGRP receptor antagonists including zavegepant and rimegepant [ ].

Techniques: Formulation

Journal: Drugs

Article Title: Zavegepant: First Approval

doi: 10.1007/s40265-023-01885-6

Figure Lengend Snippet: Features and properties of zavegepant

Article Snippet: The acquisition brought to Pfizer a portfolio of promising CGRP receptor antagonists including zavegepant and rimegepant [ ].

Techniques: Drug discovery, Ex Vivo, Produced, Inhibition